Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TAILORswitch (PADA-2): Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.

NCT07717450 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT07717450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07717450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TAILORswitch (PADA-2): Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 25, 2026
Completion date
June 25, 2032
Enrollment
370 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic invasive breast cancer